

NR¹⁰- (wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵ is selected from one of the following twenty-two groups:

1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C₁₋₅alkylX²C(O)R¹¹ (wherein X² represents -O- or -NR¹²- (in which R¹² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹¹ represents C₁₋₃alkyl, -NR¹³R¹⁴ or -OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different each represents hydrogen, C₁₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl));

A² 3) C₁₋₅alkylX³R¹⁶ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR¹⁷C(O)-, -C(O)NR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹- (wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));

4) C₁₋₅alkylX⁴C₁₋₅alkylX⁵R²² (wherein X⁴ and X⁵ which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR²³C(O)-, -C(O)NR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷- (wherein R²³, R²⁴, R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);

5) R²⁸ (wherein R²⁸ is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋

$\text{C}_{1-4}\text{alkylsulphonylC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxycarbonyl}$, $\text{C}_{1-4}\text{aminoalkyl}$, $\text{C}_{1-4}\text{alkylamino}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{amino}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkoxy}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkoxy}$ and a group $\text{-(O-)}_f(\text{C}_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $\text{C}_{1-4}\text{alkyl}$));

6) $\text{C}_{1-5}\text{alkylR}^{28}$ (wherein R^{28} is as defined hereinbefore);

7) $\text{C}_{2-5}\text{alkenylR}^{28}$ (wherein R^{28} is as defined hereinbefore);

8) $\text{C}_{2-5}\text{alkynylR}^{28}$ (wherein R^{28} is as defined hereinbefore);

A² 9) R^{29} (wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$, $\text{C}_{1-4}\text{hydroxyalkyl}$, $\text{C}_{1-4}\text{aminoalkyl}$, $\text{C}_{1-4}\text{alkylamino}$, $\text{C}_{1-4}\text{hydroxyalkoxy}$, carboxy, trifluoromethyl, cyano, $\text{-C(O)NR}^{30}\text{R}^{31}$, $\text{-NR}^{32}\text{C(O)R}^{33}$ (wherein R^{30} , R^{31} , R^{32} and R^{33} , which may be the same or different, each represents hydrogen, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and a group $\text{-(O-)}_f(\text{C}_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $\text{C}_{1-4}\text{alkyl}$));

10) $\text{C}_{1-5}\text{alkylR}^{29}$ (wherein R^{29} is as defined hereinbefore);

11) $\text{C}_{2-5}\text{alkenylR}^{29}$ (wherein R^{29} is as defined hereinbefore);

12) $\text{C}_{2-5}\text{alkynylR}^{29}$ (wherein R^{29} is as defined hereinbefore);

13) $\text{C}_{1-5}\text{alkylX}^6\text{R}^{29}$ (wherein X^6 represents -O- , -S- , -SO- , $\text{-SO}_2\text{-}$, $\text{-NR}^{34}\text{C(O)-}$, $\text{-C(O)NR}^{35}\text{-}$, $\text{SO}_2\text{NR}^{36}\text{-}$, $\text{-NR}^{37}\text{SO}_2\text{-}$ or $\text{-NR}^{38}\text{-}$ (wherein R^{34} , R^{35} , R^{36} , R^{37} and R^{38} each independently represents hydrogen, $\text{C}_{1-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and R^{29} is as defined hereinbefore);

14) $\text{C}_{2-5}\text{alkenylX}^7\text{R}^{29}$ (wherein X^7 represents -O- , -S- , -SO- , $\text{-SO}_2\text{-}$, $\text{-NR}^{39}\text{C(O)-}$, $\text{-C(O)NR}^{40}\text{-}$, $\text{-SO}_2\text{NR}^{41}\text{-}$, $\text{-NR}^{42}\text{SO}_2\text{-}$ or $\text{-NR}^{43}\text{-}$ (wherein R^{39} , R^{40} , R^{41} , R^{42} and R^{43} each independently represents hydrogen, $\text{C}_{1-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and R^{29} is as defined hereinbefore);

- 15) $C_{2-5}alkynylX^8R^{29}$ (wherein X^8 represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁴C(O)-, -C(O)NR⁴⁵-, -SO₂NR⁴⁶-, -NR⁴⁷SO₂- or -NR⁴⁸- (wherein R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined hereinbefore);
- 16) $C_{1-4}alkylX^9C_{1-4}alkylR^{29}$ (wherein X^9 represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁹C(O)-, -C(O)NR⁵⁰-, -SO₂NR⁵¹-, -NR⁵²SO₂- or -NR⁵³- (wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵² and R⁵³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined hereinbefore);
- 17) $C_{1-4}alkylX^9C_{1-4}alkylR^{28}$ (wherein X^9 and R²⁸ are as defined hereinbefore);
- 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 20) $C_{2-5}alkenylX^9C_{1-4}alkylR^{28}$ (wherein X^9 and R²⁸ are as defined hereinbefore);
- 21) $C_{2-5}alkynylX^9C_{1-4}alkylR^{28}$ (wherein X^9 and R²⁸ are as defined hereinbefore); and
- 22) $C_{1-4}alkylR^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$ (wherein X^9 is as defined hereinbefore, q is 0 or 1, r is 0 or 1, and R⁵⁴ and R⁵⁵ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group $-(O-)_f(C_{1-4}alkyl)_gringD$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), with the proviso that R⁵⁴ cannot be hydrogen);

and additionally wherein any C₁₋₅alkyl, C₂₋₅alkenyl or C₂₋₅alkynyl group in R⁵X¹ - may bear one or more substituents selected from hydroxy, halogeno and amino);

A² R¹ represents hydrogen, oxo, halogeno, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₁₋₄alkoxymethyl, C₁₋₄alkanoyl, C₁₋₄haloalkyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₃alkanoyloxy, nitro, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, N-(C₁₋₄alkylsulphonyl)amino, N-(C₁₋₄alkylsulphonyl)-N-(C₁₋₄alkyl)amino, N,N-di(C₁₋₄alkylsulphonyl)amino, a C₃₋₇alkylene chain joined to two ring C carbon atoms, C₁₋₄alkanoylaminoC₁₋₄alkyl, carboxy or a group R⁵⁶X¹⁰ (wherein X¹⁰ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁵⁷C(O)-, -C(O)NR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹- (wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵⁶ is selected from one of the following twenty-two groups:

- 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
- 2) C₁₋₅alkylX¹¹C(O)R⁶² (wherein X¹¹ represents -O- or -NR⁶³- (in which R⁶³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶² represents C₁₋₃alkyl, -NR⁶⁴R⁶⁵ or -OR⁶⁶ (wherein R⁶⁴, R⁶⁵ and R⁶⁶ which may be the same or different each represents hydrogen, C₁₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl));
- 3) C₁₋₅alkylX¹²R⁶⁷ (wherein X¹² represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR⁶⁸C(O)-, -C(O)NR⁶⁹-, -SO₂NR⁷⁰-, -NR⁷¹SO₂- or -NR⁷²- (wherein R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ and R⁷² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶⁷ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋

$\text{C}_{1-4}\text{alkoxy}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkoxy}$ and a group $\text{-(O-)}_f(\text{C}_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $\text{C}_{1-4}\text{alkyl}$));

4) $\text{C}_{1-5}\text{alkylX}^{13}\text{C}_{1-5}\text{alkylX}^{14}\text{R}^{73}$ (wherein X^{13} and X^{14} which may be the same or different are each -O- , -S- , -SO- , $\text{-SO}_2\text{-}$, $\text{-NR}^{74}\text{C(O)-}$, $\text{-C(O)NR}^{75}\text{-}$, $\text{-SO}_2\text{NR}^{76}\text{-}$, $\text{-NR}^{77}\text{SO}_2\text{-}$ or $\text{-NR}^{78}\text{-}$ (wherein R^{74} , R^{75} , R^{76} , R^{77} and R^{78} each independently represents hydrogen, $\text{C}_{1-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and R^{73} represents hydrogen, $\text{C}_{1-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$);

5) R^{79} (wherein R^{79} is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $\text{C}_{1-4}\text{cyanoalkyl}$, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{hydroxyalkyl}$, $\text{C}_{1-4}\text{alkoxy}$, $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylsulphonylC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxycarbonyl}$, $\text{C}_{1-4}\text{aminoalkyl}$, $\text{C}_{1-4}\text{alkylamino}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{amino}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkoxy}$, $\text{di}(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkoxy}$ and a group $\text{-(O-)}_f(\text{C}_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $\text{C}_{1-4}\text{alkyl}$));

6) $\text{C}_{1-5}\text{alkylR}^{79}$ (wherein R^{79} is as defined hereinbefore);

7) $\text{C}_{2-5}\text{alkenylR}^{79}$ (wherein R^{79} is as defined hereinbefore);

8) $\text{C}_{2-5}\text{alkynylR}^{79}$ (wherein R^{79} is as defined hereinbefore);

9) R^{80} (wherein R^{80} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$, $\text{C}_{1-4}\text{hydroxyalkyl}$, $\text{C}_{1-4}\text{aminoalkyl}$, $\text{C}_{1-4}\text{alkylamino}$, $\text{C}_{1-4}\text{hydroxyalkoxy}$, carboxy, trifluoromethyl, cyano, $\text{-C(O)NR}^{81}\text{R}^{82}$, $\text{-NR}^{83}\text{C(O)R}^{84}$ (wherein R^{81} , R^{82} , R^{83} and R^{84} , which may be the same or different, each represents hydrogen, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxyC}_{2-3}\text{alkyl}$) and a group $\text{-(O-)}_f(\text{C}_{1-4}\text{alkyl})_g\text{ringD}$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated

heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));

10) C₁₋₅alkylR⁸⁰ (wherein R⁸⁰ is as defined hereinbefore);

11) C₂₋₅alkenylR⁸⁰ (wherein R⁸⁰ is as defined hereinbefore);

12) C₂₋₅alkynylR⁸⁰ (wherein R⁸⁰ is as defined hereinbefore);

13) C₁₋₅alkylX¹⁵R⁸⁰ (wherein X¹⁵ represents -O-, -S-, -SO-, -SO₂-, -NR⁸⁵C(O)-, -C(O)NR⁸⁶-, -SO₂NR⁸⁷-, -NR⁸⁸SO₂- or -NR⁸⁹- (wherein R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸ and R⁸⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined hereinbefore);

14) C₂₋₅alkenylX¹⁶R⁸⁰ (wherein X¹⁶ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁰C(O)-, -C(O)NR⁹¹-, -SO₂NR⁹²-, -NR⁹³SO₂- or -NR⁹⁴- (wherein R⁹⁰, R⁹¹, R⁹², R⁹³ and R⁹⁴ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined hereinbefore);

15) C₂₋₅alkynylX¹⁷R⁸⁰ (wherein X¹⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁵C(O)-, -C(O)NR⁹⁶-, -SO₂NR⁹⁷-, -NR⁹⁸SO₂- or -NR⁹⁹- (wherein R⁹⁵, R⁹⁶, R⁹⁷, R⁹⁸ and R⁹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined hereinbefore);

16) C₁₋₄alkylX¹⁸C₁₋₄alkylR⁸⁰ (wherein X¹⁸ represents -O-, -S-, -SO-, -SO₂-, -NR¹⁰⁰C(O)-, -C(O)NR¹⁰¹-, -SO₂NR¹⁰²-, -NR¹⁰³SO₂- or -NR¹⁰⁴- (wherein R¹⁰⁰, R¹⁰¹, R¹⁰², R¹⁰³ and R¹⁰⁴ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined hereinbefore);

17) C₁₋₄alkylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined hereinbefore);

18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;

19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;

20) C₂₋₅alkenylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined hereinbefore);

21) C₂₋₅alkynylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined hereinbefore); and

A2 22) $C_{1-4}alkylR^{105}(C_{1-4}alkyl)_x(X^{18})_yR^{106}$ (wherein X^{18} is as defined hereinbefore, x is 0 or 1, y is 0 or 1, and R^{105} and R^{106} are each independently selected from hydrogen, $C_{1-3}alkyl$, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}alkyl$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}alkoxy$ and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $di(C_{1-4}alkyl)amino$, $C_{1-4}alkylaminoC_{1-4}alkyl$, $di(C_{1-4}alkyl)aminoC_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, $di(C_{1-4}alkyl)aminoC_{1-4}alkoxy$ and a group $-(O-)_f(C_{1-4}alkyl)_gringD$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}alkyl$) with the proviso that R^{105} cannot be hydrogen);
and additionally wherein any $C_{1-5}alkyl$, $C_{2-5}alkenyl$ or $C_{2-5}alkynyl$ group in $R^{56}X^{10-}$ may bear one or more substituents selected from hydroxy, halogeno and amino);
or a salt thereof, or a prodrug thereof for example an ester or an amide, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

* * * * *

Please replace the paragraph on page 15, extending from line 24 to line 32 with the following amended paragraph:

A3 Advantageously R^{105} and R^{106} are each independently a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-3}cyanoalkyl$, $C_{1-3}alkyl$, $C_{1-3}hydroxyalkyl$, $C_{1-3}alkoxy$, $C_{1-2}alkoxyC_{1-3}alkyl$, $C_{1-2}alkylsulphonylC_{1-3}alkyl$, $C_{1-3}alkoxycarbonyl$, $C_{1-3}alkylamino$, $di(C_{1-3}alkyl)amino$, $C_{1-3}alkylaminoC_{1-3}alkyl$, $di(C_{1-3}alkyl)aminoC_{1-3}alkyl$, $C_{1-3}alkylaminoC_{1-3}alkoxy$, $di(C_{1-3}alkyl)aminoC_{1-3}alkoxy$ and a group $-(O-)_f(C_{1-3}alkyl)_gringD$ (wherein f is 0 or 1, g is 0 or 1

A3 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₃alkyl).

* * * * *

Please replace the paragraph extending from page 20, line 30 to page 21, line 5 with the following amended paragraph:

A4 Advantageously R⁵⁴ and R⁵⁵ are each independently a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₃cyanoalkyl, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy, C₁₋₂alkoxyC₁₋₃alkyl, C₁₋₂alkylsulphonylC₁₋₃alkyl, C₁₋₃alkoxycarbonyl and a group $-(O)_f(C_{1-3}alkyl)_g ringD$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₃alkyl).

* * * * *

Please replace the paragraphs extending from page 22, line 7 to page 23, line 8 with the following amended paragraphs:

AS 3) C₂₋₄alkylX³R¹⁶ (wherein X³ is as hereinbefore defined and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₃alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -

(-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));

4) C₂₋₃alkylX⁴C₂₋₃alkylX⁵R²² (wherein X⁴ and X⁵ are as hereinbefore defined and R²² represents hydrogen or C₁₋₃alkyl);

5) R²⁸ (wherein R²⁸ is as defined hereinbefore);

AS 6) C₁₋₅alkylR¹⁰⁷ (wherein R¹⁰⁷ is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C₁₋₅alkyl through a carbon atom and which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group (-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl)) or C₂₋₅alkylR¹⁰⁸ (wherein R¹⁰⁸ is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, of which one is N and the other may be selected independently from O, S and N, which heterocyclic group is linked to C₂₋₅alkyl through a nitrogen atom and which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group (-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));

* * * * *

Please replace the paragraph extending from page 28, line 12 to page 30, line 21 with the following amended paragraph:

More preferably R^2 represents hydroxy, C_{1-3} alkyl, amino or R^5X^1 - [wherein X^1 is as hereinbefore defined and R^5 represents methyl, ethyl, benzyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphinyl)ethyl, 2-(methylsulphonyl)ethyl, 2-(ethylsulphinyl)ethyl, 2-(ethylsulphonyl)ethyl, 2-(N,N-dimethylsulphamoyl)ethyl, 2-(N-methylsulphamoyl)ethyl, 2-sulphamoyl, 2-(methylamino)ethyl, 3-(methylamino)propyl, 2-(ethylamino)ethyl, 3-(ethylamino)propyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-(N,N-diethylamino)ethyl, 3-(N,N-diethylamino)propyl, 2-(N-methyl-N-methylsulphonylamino)ethyl, 3-(N-methyl-N-methylsulphonylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(methylpiperidino)ethyl, 3-(methylpiperidino)propyl, 2-(ethylpiperidino)ethyl, 3-(ethylpiperidino)propyl, 2-((2-methoxyethyl)piperidino)ethyl, 3-((2-methoxyethyl)piperidino)propyl, 2-((2-methylsulphonyl)ethylpiperidino)ethyl, 3-((2-methylsulphonyl)ethylpiperidino)propyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, 2-(piperidin-3-yl)ethyl, 2-(piperidin-4-yl)ethyl, 3-(piperidin-3-yl)propyl, 3-(piperidin-4-yl)propyl, 2-(piperidin-2-yl)ethyl, 3-(piperidin-2-yl)propyl, (1-methylpiperidin-3-yl)methyl, (1-methylpiperidin-4-yl)methyl, (1-cyanomethylpiperidin-3-yl)methyl, (1-cyanomethylpiperidin-4-yl)methyl, 2-(methylpiperidin-3-yl)ethyl, 2-(methylpiperidin-4-yl)ethyl, 2-(1-cyanomethylpiperidin-3-yl)ethyl, 2-(1-cyanomethylpiperidin-4-yl)ethyl, 3-(methylpiperidin-3-yl)propyl, 3-(methylpiperidin-4-yl)propyl, 3-(1-cyanomethylpiperidin-3-yl)propyl, 3-(1-cyanomethylpiperidin-4-yl)propyl, 2-(ethylpiperidin-3-yl)ethyl, 2-(ethylpiperidin-4-yl)ethyl, 3-(ethylpiperidin-3-yl)propyl, 3-(ethylpiperidin-4-yl)propyl, ((2-methoxyethyl)piperidin-3-yl)methyl, ((2-methoxyethyl)piperidin-4-yl)methyl, 2-((2-methoxyethyl)piperidin-3-yl)ethyl, 2-((2-methoxyethyl)piperidin-4-yl)ethyl, 3-((2-methoxyethyl)piperidin-3-yl)propyl, 3-((2-methoxyethyl)piperidin-4-yl)propyl, (1-(2-methylsulphonyl)ethyl)piperidin-3-yl)methyl, (1-(2-methylsulphonyl)ethyl)piperidin-4-yl)methyl, 2-((2-methylsulphonyl)ethyl)piperidin-3-yl)ethyl, 2-((2-methylsulphonyl)ethyl)piperidin-4-yl)ethyl, 3-((2-methylsulphonyl)ethyl)piperidin-3-yl)propyl, 3-((2-methylsulphonyl)ethyl)piperidin-4-yl)propyl, 1-isopropylpiperidin-2-

ylmethyl, 1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl, 2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl, 2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl, 3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl, 2-(piperidin-4-yloxy)ethyl, 3-(piperidin-4-yloxy)propyl, 2-(1-(cyanomethyl)piperidin-4-yloxy)ethyl, 3-(1-(cyanomethyl)piperidin-4-yloxy)propyl, 2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethyl, 3-(1-(2-cyanoethyl)piperidin-4-yloxy)propyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, (pyrrolidin-2-yl)methyl, 2-(pyrrolidin-1-yl)ethyl, 3-(pyrrolidin-1-yl)propyl, (2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, 5(R)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (5S)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (1,3-dioxolan-2-yl)methyl, 2-(1,3-dioxolan-2-yl)ethyl, 2-(2-methoxyethylamino)ethyl, 2-(N-(2-methoxyethyl)-N-methylamino)ethyl, 2-(2-hydroxyethylamino)ethyl, 3-(2-methoxyethylamino)propyl, 3-(N-(2-methoxyethyl)-N-methylamino)propyl, 3-(2-hydroxyethylamino)propyl, 2-methylthiazol-4-ylmethyl, 2-acetamidothiazol-4-ylmethyl, 1-methylimidazol-2-ylmethyl, 2-(imidazol-1-yl)ethyl, 2-(2-methylimidazol-1-yl)ethyl, 2-(2-ethylimidazol-1-yl)ethyl, 3-(2-methylimidazol-1-yl)propyl, 3-(2-ethylimidazol-1-yl)propyl, 2-(1,2,3-triazol-1-yl)ethyl, 2-(1,2,3-triazol-2-yl)ethyl, 2-(1,2,4-triazol-1-yl)ethyl, 2-(1,2,4-triazol-4-yl)ethyl, 4-pyridylmethyl, 2-(4-pyridyl)ethyl, 3-(4-pyridyl)propyl, 2-(4-pyridyloxy)ethyl, 2-(4-pyridylamino)ethyl, 2-(4-oxo-1,4-dihydro-1-pyridyl)ethyl, 2-(2-oxo-imidazolidin-1-yl)ethyl, 3-(2-oxo-imidazolidin-1-yl)propyl, 2-thiomorpholinoethyl, 3-thiomorpholinopropyl, 2-(1,1-dioxothiomorpholino)ethyl, 3-(1,1-dioxothiomorpholino)propyl, 2-(2-methoxyethoxy)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl, 3-(methylsulphinyl)propyl, 3-(methylsulphonyl)propyl, 3-(ethylsulphinyl)propyl, 3-(ethylsulphonyl)propyl, 2-(5-methyl-1,2,4-triazol-1-yl)ethyl, morpholino, 2-(N-(1-methylimidazol-4-ylsulphonyl)-N-methylamino)ethyl, 2-(N-(3-morpholinopropylsulphonyl)-N-methylamino)ethyl, 2-(N-methyl-N-4-pyridylamino)ethyl, 3-(4-oxidomorpholino)propyl, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethyl, 3-(2-(4-methylpiperazin-1-yl)ethoxy)propyl, 2-(2-morpholinoethoxy)ethyl, 3-(2-morpholinoethoxy)propyl, 2-(tetrahydropyran-4-yloxy)ethyl, 3-(tetrahydropyran-4-yloxy)propyl, 2-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)vinyl, 3-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)prop-2-en-1-yl, 1-(2-pyrrolidinylethyl)piperidin-4-ylmethyl, 1-(3-

A6 pyrrolidinylpropyl)piperidin-4-ylmethyl, 1-(2-piperidinylethyl)piperidin-4-ylmethyl, 1-(3-piperidinylpropyl)piperidin-4-ylmethyl, 1-(2-morpholinoethyl)piperidin-4-ylmethyl, 1-(3-morpholinopropyl)piperidin-4-ylmethyl, 1-(2-thiomorpholinoethyl)piperidin-4-ylmethyl, 1-(3-thiomorpholinopropyl)piperidin-4-ylmethyl, 1-(2-azetidinyethyl)piperidin-4-ylmethyl, [or] 1-(3-azetidinypropyl)piperidin-4-ylmethyl, 3-morpholino-2-hydroxypropyl, (2R)-3-morpholino-2-hydroxypropyl, (2S)-3-morpholino-2-hydroxypropyl, 3-piperidino-2-hydroxypropyl, (2R)-3-piperidino-2-hydroxypropyl, (2S)-3-piperidino-2-hydroxypropyl, 3-pyrrolidin-1-yl-2-hydroxypropyl, (2R)-3-pyrrolidin-1-yl-2-hydroxypropyl, (2S)-3-pyrrolidin-1-yl-2-hydroxypropyl, 3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2R)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2S)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, 3-(N,N-diethylamino)-2-hydroxypropyl, (2R)-3-(N,N-diethylamino)-2-hydroxypropyl, (2S)-3-(N,N-diethylamino)-2-hydroxypropyl, 3-(isopropylamino)-2-hydroxypropyl, (2R)-3-(isopropylamino)-2-hydroxypropyl, (2S)-3-(isopropylamino)-2-hydroxypropyl, 3-(N,N-diisopropylamino)-2-hydroxypropyl, (2R)-3-(N,N-diisopropylamino)-2-hydroxypropyl or (2S)-3-(N,N-diisopropylamino)-2-hydroxypropyl].

* * * * *

Please replace the paragraph extending from page 30, line 22 to page 32, line 30 with the following amended paragraph:

A7 Particularly R² represents C₁₋₃alkyl, amino or R⁵X¹ - [wherein X¹ is as hereinbefore defined and R⁵ represents ethyl, benzyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphinyl)ethyl, 2-(methylsulphonyl)ethyl, 2-(ethylsulphinyl)ethyl, 2-(ethylsulphonyl)ethyl, 2-(N,N-dimethylsulphamoyl)ethyl, 2-(N-methylsulphamoyl)ethyl, 2-sulphamoylethyl, 2-(methylamino)ethyl, 3-(methylamino)propyl, 2-(ethylamino)ethyl, 3-(ethylamino)propyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-(N,N-diethylamino)ethyl, 3-(N,N-diethylamino)propyl, 2-(N-methyl-N-methylsulphonylamino)ethyl, 3-(N-methyl-N-methylsulphonylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(methylpiperidino)ethyl, 3-(methylpiperidino)propyl, 2-

A7 (ethylpiperidino)ethyl, 3-(ethylpiperidino)propyl, 2-((2-methoxyethyl)piperidino)ethyl, 3-((2-methoxyethyl)piperidino)propyl, 2-((2-methylsulphonyl)ethylpiperidino)ethyl, 3-((2-methylsulphonyl)ethylpiperidino)propyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, 2-(piperidin-3-yl)ethyl, 2-(piperidin-4-yl)ethyl, 3-(piperidin-3-yl)propyl, 3-(piperidin-4-yl)propyl, 2-(piperidin-2-yl)ethyl, 3-(piperidin-2-yl)propyl, (1-methylpiperidin-3-yl)methyl, (1-methylpiperidin-4-yl)methyl, (1-cyanomethylpiperidin-3-yl)methyl, (1-cyanomethylpiperidin-4-yl)methyl, 2-(methylpiperidin-3-yl)ethyl, 2-(methylpiperidin-4-yl)ethyl, 2-(1-cyanomethylpiperidin-3-yl)ethyl, 2-(1-cyanomethylpiperidin-4-yl)ethyl, 3-(methylpiperidin-3-yl)propyl, 3-(methylpiperidin-4-yl)propyl, 3-(1-cyanomethylpiperidin-3-yl)propyl, 3-(1-cyanomethylpiperidin-4-yl)propyl, 2-(ethylpiperidin-3-yl)ethyl, 2-(ethylpiperidin-4-yl)ethyl, 3-(ethylpiperidin-3-yl)propyl, 3-(ethylpiperidin-4-yl)propyl, ((2-methoxyethyl)piperidin-3-yl)methyl, ((2-methoxyethyl)piperidin-4-yl)methyl, 2-((2-methoxyethyl)piperidin-3-yl)ethyl, 2-((2-methoxyethyl)piperidin-4-yl)ethyl, 3-((2-methoxyethyl)piperidin-3-yl)propyl, 3-((2-methoxyethyl)piperidin-4-yl)propyl, (1-(2-methylsulphonyl)ethyl)piperidin-3-yl)methyl, (1-(2-methylsulphonyl)ethyl)piperidin-4-yl)methyl, 2-((2-methylsulphonyl)ethyl)piperidin-3-yl)ethyl, 2-((2-methylsulphonyl)ethyl)piperidin-4-yl)ethyl, 3-((2-methylsulphonyl)ethyl)piperidin-3-yl)propyl, 3-((2-methylsulphonyl)ethyl)piperidin-4-yl)propyl, 1-isopropylpiperidin-2-ylmethyl, 1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl, 2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl, 2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl, 3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl, 2-(piperidin-4-yloxy)ethyl, 3-(piperidin-4-yloxy)propyl, 2-(1-(cyanomethyl)piperidin-4-yloxy)ethyl, 3-(1-(cyanomethyl)piperidin-4-yloxy)propyl, 2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethyl, 3-(1-(2-cyanoethyl)piperidin-4-yloxy)propyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, (pyrrolidin-2-yl)methyl, 2-(pyrrolidin-1-yl)ethyl, 3-(pyrrolidin-1-yl)propyl, (2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, 5(R)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (5S)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (1,3-dioxolan-2-yl)methyl, 2-(1,3-dioxolan-2-yl)ethyl, 2-(2-methoxyethylamino)ethyl, 2-(N-(2-methoxyethyl)-N-methylamino)ethyl, 2-(2-hydroxyethylamino)ethyl, 3-(2-methoxyethylamino)propyl, 3-(N-(2-methoxyethyl)-N-methylamino)propyl, 3-(2-

A7
hydroxyethylamino)propyl, 2-methylthiazol-4-ylmethyl, 2-acetamidothiazol-4-ylmethyl, 1-methylimidazol-2-ylmethyl, 2-(imidazol-1-yl)ethyl, 2-(2-methylimidazol-1-yl)ethyl, 2-(2-ethylimidazol-1-yl)ethyl, 3-(2-methylimidazol-1-yl)propyl, 3-(2-ethylimidazol-1-yl)propyl, 2-(1,2,3-triazol-1-yl)ethyl, 2-(1,2,3-triazol-2-yl)ethyl, 2-(1,2,4-triazol-1-yl)ethyl, 2-(1,2,4-triazol-4-yl)ethyl, 4-pyridylmethyl, 2-(4-pyridyl)ethyl, 3-(4-pyridyl)propyl, 2-(4-pyridyloxy)ethyl, 2-(4-pyridylamino)ethyl, 2-(4-oxo-1,4-dihydro-1-pyridyl)ethyl, 2-(2-oxoimidazolidin-1-yl)ethyl, 3-(2-oxoimidazolidin-1-yl)propyl, 2-thiomorpholinoethyl, 3-thiomorpholinopropyl, 2-(1,1-dioxothiomorpholino)ethyl, 3-(1,1-dioxothiomorpholino)propyl, 2-(2-methoxyethoxy)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl, 3-(methylsulphinyl)propyl, 3-(methylsulphonyl)propyl, 3-(ethylsulphinyl)propyl, 3-(ethylsulphonyl)propyl, 2-(5-methyl-1,2,4-triazol-1-yl)ethyl, morpholino, 2-((N-(1-methylimidazol-4-ylsulphonyl)-N-methyl)amino)ethyl, 2-((N-(3-morpholinopropylsulphonyl)-N-methyl)amino)ethyl, 2-((N-methyl-N-4-pyridyl)amino)ethyl, 3-(4-oxidomorpholino)propyl, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethyl, 3-(2-(4-methylpiperazin-1-yl)ethoxy)propyl, 2-(2-morpholinoethoxy)ethyl, 3-(2-morpholinoethoxy)propyl, 2-(tetrahydropyran-4-yloxy)ethyl, 3-(tetrahydropyran-4-yloxy)propyl, 2-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)vinyl, 3-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)prop-2-en-1-yl, 1-(2-pyrrolidinylethyl)piperidin-4-ylmethyl, 1-(3-pyrrolidinylpropyl)piperidin-4-ylmethyl, 1-(2-piperidinyloethyl)piperidin-4-ylmethyl, 1-(3-piperidinylpropyl)piperidin-4-ylmethyl, 1-(2-morpholinoethyl)piperidin-4-ylmethyl, 1-(3-morpholinopropyl)piperidin-4-ylmethyl, 1-(2-thiomorpholinoethyl)piperidin-4-ylmethyl, 1-(3-thiomorpholinopropyl)piperidin-4-ylmethyl, 1-(2-azetidinyloethyl)piperidin-4-ylmethyl, 1-(3-azetidinyloethyl)piperidin-4-ylmethyl, 3-morpholino-2-hydroxypropyl, (2R)-3-morpholino-2-hydroxypropyl, (2S)-3-morpholino-2-hydroxypropyl, 3-piperidino-2-hydroxypropyl, (2R)-3-piperidino-2-hydroxypropyl, (2S)-3-piperidino-2-hydroxypropyl, 3-pyrrolidin-1-yl-2-hydroxypropyl, (2R)-3-pyrrolidin-1-yl-2-hydroxypropyl, (2S)-3-pyrrolidin-1-yl-2-hydroxypropyl, 3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2R)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2S)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, 3-(N,N-diethylamino)-2-hydroxypropyl, (2R)-3-(N,N-diethylamino)-2-hydroxypropyl, (2S)-3-(N,N-diethylamino)-2-hydroxypropyl, 3-(isopropylamino)-2-hydroxypropyl, (2R)-3-(isopropylamino)-2-hydroxypropyl, (2S)-3-(isopropylamino)-2-hydroxypropyl, 3-(N,N-

A7 diisopropylamino)-2-hydroxypropyl, (2R)-3-(N,N-diisopropylamino)-2-hydroxypropyl or
(2S)-3-(N,N-diisopropylamino)-2-hydroxypropyl].

* * * * *

Please replace the paragraph extending from page 32, line 31 to page 35, line 3 with
the following amended paragraph:

A8 More particularly R² represents C₁₋₃alkyl, amino or R⁵X¹ - [wherein X¹ is as hereinbefore
defined and R⁵ represents ethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, 3-
hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-(methylsulphinyl)ethyl, 2-
(methylsulphonyl)ethyl, 2-(ethylsulphinyl)ethyl, 2-(ethylsulphonyl)ethyl, 2-(N,N-
dimethylsulphamoyl)ethyl, 2-(N-methylsulphamoyl)ethyl, 2-sulphamoylethyl, 2-
(methylamino)ethyl, 3-(methylamino)propyl, 2-(ethylamino)ethyl, 3-(ethylamino)propyl, 2-
(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-(N,N-diethylamino)ethyl, 3-
(N,N-diethylamino)propyl, 2-(N-methyl-N-methylsulphonylamino)ethyl, 3-(N-methyl-N-
methylsulphonylamino)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-
piperidinopropyl, 2-(methylpiperidino)ethyl, 3-(methylpiperidino)propyl, 2-
(ethylpiperidino)ethyl, 3-(ethylpiperidino)propyl, 2-((2-methoxyethyl)piperidino)ethyl, 3-((2-
methoxyethyl)piperidino)propyl, 2-((2-methylsulphonyl)ethylpiperidino)ethyl, 3-((2-
methylsulphonyl)ethylpiperidino)propyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, 2-
(piperidin-3-yl)ethyl, 2-(piperidin-4-yl)ethyl, 3-(piperidin-3-yl)propyl, 3-(piperidin-4-
yl)propyl, 2-(piperidin-2-yl)ethyl, 3-(piperidin-2-yl)propyl, (1-methylpiperidin-3-yl)methyl,
(1-methylpiperidin-4-yl)methyl, (1-cyanomethylpiperidin-3-yl)methyl, (1-
cyanomethylpiperidin-4-yl)methyl, 2-(methylpiperidin-3-yl)ethyl, 2-(methylpiperidin-4-
yl)ethyl, 2-(1-cyanomethylpiperidin-3-yl)ethyl, 2-(1-cyanomethylpiperidin-4-yl)ethyl, 3-
(methylpiperidin-3-yl)propyl, 3-(methylpiperidin-4-yl)propyl, 3-(1-cyanomethylpiperidin-3-
yl)propyl, 3-(1-cyanomethylpiperidin-4-yl)propyl, 2-(ethylpiperidin-3-yl)ethyl, 2-
(ethylpiperidin-4-yl)ethyl, 3-(ethylpiperidin-3-yl)propyl, 3-(ethylpiperidin-4-yl)propyl, ((2-
methoxyethyl)piperidin-3-yl)methyl, ((2-methoxyethyl)piperidin-4-yl)methyl, 2-((2-
methoxyethyl)piperidin-3-yl)ethyl, 2-((2-methoxyethyl)piperidin-4-yl)ethyl, 3-((2-

methoxyethyl)piperidin-3-yl)propyl, 3-((2-methoxyethyl)piperidin-4-yl)propyl, (1-(2-methylsulphonylethyl)piperidin-3-yl)methyl, (1-(2-methylsulphonylethyl)piperidin-4-yl)methyl, 2-((2-methylsulphonylethyl)piperidin-3-yl)ethyl, 2-((2-methylsulphonylethyl)piperidin-4-yl)ethyl, 3-((2-methylsulphonylethyl)piperidin-3-yl)propyl, 3-((2-methylsulphonylethyl)piperidin-4-yl)propyl, 1-isopropylpiperidin-2-ylmethyl, 1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl, 2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl, 2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl, 3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl, 2-(piperidin-4-yloxy)ethyl, 3-(piperidin-4-yloxy)propyl, 2-(1-(cyanomethyl)piperidin-4-yloxy)ethyl, 3-(1-(cyanomethyl)piperidin-4-yloxy)propyl, 2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethyl, 3-(1-(2-cyanoethyl)piperidin-4-yloxy)propyl, 2-(piperazin-1-yl)ethyl, 3-(piperazin-1-yl)propyl, (pyrrolidin-2-yl)methyl, 2-(pyrrolidin-1-yl)ethyl, 3-(pyrrolidin-1-yl)propyl, (2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, 5(R)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (5S)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methyl, (1,3-dioxolan-2-yl)methyl, 2-(1,3-dioxolan-2-yl)ethyl, 2-(2-methoxyethylamino)ethyl, 2-(N-(2-methoxyethyl)-N-methylamino)ethyl, 2-(2-hydroxyethylamino)ethyl, 3-(2-methoxyethylamino)propyl, 3-(N-(2-methoxyethyl)-N-methylamino)propyl, 3-(2-hydroxyethylamino)propyl, 2-(1,2,3-triazol-1-yl)ethyl, 2-(1,2,3-triazol-2-yl)ethyl, 2-(1,2,4-triazol-1-yl)ethyl, 2-(1,2,4-triazol-4-yl)ethyl, 4-pyridylmethyl, 2-(4-pyridyl)ethyl, 3-(4-pyridyl)propyl, 2-(4-pyridyloxy)ethyl, 2-(4-pyridylamino)ethyl, 2-(4-oxo-1,4-dihydro-1-pyridyl)ethyl, 2-(2-oxo-imidazolidin-1-yl)ethyl, 3-(2-oxo-imidazolidin-1-yl)propyl, 2-thiomorpholinoethyl, 3-thiomorpholinopropyl, 2-(1,1-dioxothiomorpholino)ethyl, 3-(1,1-dioxothiomorpholino)propyl, 2-(2-methoxyethoxy)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl, 3-(methylsulphinyl)propyl, 3-(methylsulphonyl)propyl, 3-(ethylsulphinyl)propyl, 3-(ethylsulphonyl)propyl, 2-(5-methyl-1,2,4-triazol-1-yl)ethyl, morpholino, 2-((N-(3-morpholinopropylsulphonyl)-N-methyl)amino)ethyl, 2-((N-methyl-N-4-pyridyl)amino)ethyl, 3-(4-oximorpholino)propyl, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethyl, 3-(2-(4-methylpiperazin-1-yl)ethoxy)propyl, 2-(2-morpholinoethoxy)ethyl, 3-(2-morpholinoethoxy)propyl, 2-(tetrahydropyran-4-yloxy)ethyl, 3-(tetrahydropyran-4-yloxy)propyl, 2-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)vinyl, 3-((2-(pyrrolidin-1-

A8
 yl)ethyl)carbamoyl)prop-2-en-1-yl, 1-(2-pyrrolidinyloethyl)piperidin-4-ylmethyl, 1-(3-pyrrolidinylpropyl)piperidin-4-ylmethyl, 1-(2-piperidinylethyl)piperidin-4-ylmethyl, 1-(3-piperidinylpropyl)piperidin-4-ylmethyl, 1-(2-morpholinoethyl)piperidin-4-ylmethyl, 1-(3-morpholinopropyl)piperidin-4-ylmethyl, 1-(2-thiomorpholinoethyl)piperidin-4-ylmethyl, 1-(3-thiomorpholinopropyl)piperidin-4-ylmethyl, 1-(2-azetidinyloethyl)piperidin-4-ylmethyl, 1-(3-azetidinyloethyl)piperidin-4-ylmethyl, 3-morpholino-2-hydroxypropyl, (2R)-3-morpholino-2-hydroxypropyl, (2S)-3-morpholino-2-hydroxypropyl, 3-piperidino-2-hydroxypropyl, (2R)-3-piperidino-2-hydroxypropyl, (2S)-3-piperidino-2-hydroxypropyl, 3-pyrrolidin-1-yl-2-hydroxypropyl, (2R)-3-pyrrolidin-1-yl-2-hydroxypropyl, (2S)-3-pyrrolidin-1-yl-2-hydroxypropyl, 3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2R)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, (2S)-3-(1-methylpiperazin-4-yl)-2-hydroxypropyl, 3-(N,N-diethylamino)-2-hydroxypropyl, (2R)-3-(N,N-diethylamino)-2-hydroxypropyl, (2S)-3-(N,N-diethylamino)-2-hydroxypropyl, 3-(isopropylamino)-2-hydroxypropyl, (2R)-3-(isopropylamino)-2-hydroxypropyl, (2S)-3-(isopropylamino)-2-hydroxypropyl, 3-(N,N-diisopropylamino)-2-hydroxypropyl, (2R)-3-(N,N-diisopropylamino)-2-hydroxypropyl or (2S)-3-(N,N-diisopropylamino)-2-hydroxypropyl].

* * * * *

Please replace the paragraph extending from page 35, line 4 to page 37, line 11 with the following amended paragraph:

A9
 In another aspect R² represents ethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-(methylsulphinyl)ethoxy, 2-(methylsulphonyl)ethoxy, 2-(ethylsulphinyl)ethoxy, 2-(ethylsulphonyl)ethoxy, 2-(N,N-dimethylsulphamoyl)ethoxy, 2-(N-methylsulphamoyl)ethoxy, 2-sulphamoylethoxy, 2-(methylamino)ethoxy, 3-(methylamino)propoxy, 2-(ethylamino)ethoxy, 3-(ethylamino)propoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-(N,N-diethylamino)ethoxy, 3-(N,N-diethylamino)propoxy, 2-(N-methyl-N-methylsulphonylamino)ethoxy, 3-(N-methyl-N-methylsulphonylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-

A9
piperidinoethoxy, 3-piperidinopropoxy, 2-(methylpiperidino)ethoxy, 3-(methylpiperidino)propoxy, 2-(ethylpiperidino)ethoxy, 3-(ethylpiperidino)propoxy, 2-((2-methoxyethyl)piperidino)ethoxy, 3-((2-methoxyethyl)piperidino)propoxy, 2-((2-methylsulphonyl)ethylpiperidino)ethoxy, 3-((2-methylsulphonyl)ethylpiperidino)propoxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-(piperidin-3-yl)ethoxy, 2-(piperidin-4-yl)ethoxy, 3-(piperidin-3-yl)propoxy, 3-(piperidin-4-yl)propoxy, 2-(piperidin-2-yl)ethoxy, 3-(piperidin-2-yl)propoxy, (1-methylpiperidin-3-yl)methoxy, (1-methylpiperidin-4-yl)methoxy, (1-cyanomethylpiperidin-3-yl)methoxy, (1-cyanomethylpiperidin-4-yl)methoxy, 2-(methylpiperidin-3-yl)ethoxy, 2-(methylpiperidin-4-yl)ethoxy, 2-(1-cyanomethylpiperidin-3-yl)ethoxy, 2-(1-cyanomethylpiperidin-4-yl)ethoxy, 3-(methylpiperidin-3-yl)propoxy, 3-(methylpiperidin-4-yl)propoxy, 3-(1-cyanomethylpiperidin-3-yl)propoxy, 3-(1-cyanomethylpiperidin-4-yl)propoxy, 2-(ethylpiperidin-3-yl)ethoxy, 2-(ethylpiperidin-4-yl)ethoxy, 3-(ethylpiperidin-3-yl)propoxy, 3-(ethylpiperidin-4-yl)propoxy, ((2-methoxyethyl)piperidin-3-yl)methoxy, ((2-methoxyethyl)piperidin-4-yl)methoxy, 2-((2-methoxyethyl)piperidin-3-yl)ethoxy, 2-((2-methoxyethyl)piperidin-4-yl)ethoxy, 3-((2-methoxyethyl)piperidin-3-yl)propoxy, 3-((2-methoxyethyl)piperidin-4-yl)propoxy, (1-(2-methylsulphonylethyl)piperidin-3-yl)methoxy, (1-(2-methylsulphonylethyl)piperidin-4-yl)methoxy, 2-((2-methylsulphonylethyl)piperidin-3-yl)ethoxy, 2-((2-methylsulphonylethyl)piperidin-4-yl)ethoxy, 3-((2-methylsulphonylethyl)piperidin-3-yl)propoxy, 3-((2-methylsulphonylethyl)piperidin-4-yl)propoxy, 1-isopropylpiperidin-2-ylmethoxy, 1-isopropylpiperidin-3-ylmethoxy, 1-isopropylpiperidin-4-ylmethoxy, 2-(1-isopropylpiperidin-2-yl)ethoxy, 2-(1-isopropylpiperidin-3-yl)ethoxy, 2-(1-isopropylpiperidin-4-yl)ethoxy, 3-(1-isopropylpiperidin-2-yl)propoxy, 3-(1-isopropylpiperidin-3-yl)propoxy, 3-(1-isopropylpiperidin-4-yl)propoxy, 2-(piperidin-4-yloxy)ethoxy, 3-(piperidin-4-yloxy)propoxy, 2-(1-(cyanomethyl)piperidin-4-yloxy)ethoxy, 3-(1-(cyanomethyl)piperidin-4-yloxy)propoxy, 2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethoxy, 3-(1-(2-cyanoethyl)piperidin-4-yloxy)propoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, (pyrrolidin-2-yl)methoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, (2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methoxy, 5(R)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methoxy, (5S)-(2-oxo-tetrahydro-2H-pyrrolidin-5-yl)methoxy, (1,3-dioxolan-2-yl)methoxy, 2-(1,3-dioxolan-2-

yl)ethoxy, 2-(2-methoxyethylamino)ethoxy, 2-(N-(2-methoxyethyl)-N-methylamino)ethoxy, 2-(2-hydroxyethylamino)ethoxy, 3-(2-methoxyethylamino)propoxy, 3-(N-(2-methoxyethyl)-N-methylamino)propoxy, 3-(2-hydroxyethylamino)propoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 2-(1,2,3-triazol-2-yl)ethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, 2-(1,2,4-triazol-4-yl)ethoxy, 4-pyridylmethoxy, 2-(4-pyridyl)ethoxy, 3-(4-pyridyl)propoxy, 2-(4-pyridyloxy)ethoxy, 2-(4-pyridylamino)ethoxy, 2-(4-oxo-1,4-dihydro-1-pyridyl)ethoxy, 2-(2-oxo-imidazolidin-1-yl)ethoxy, 3-(2-oxo-imidazolidin-1-yl)propoxy, 2-thiomorpholinoethoxy, 3-thiomorpholinopropoxy, 2-(1,1-dioxothiomorpholino)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(2-methoxyethoxy)ethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(methylsulphinyl)propoxy, 3-(methylsulphonyl)propoxy, 3-(ethylsulphinyl)propoxy, 3-(ethylsulphonyl)propoxy, 2-(5-methyl-1,2,4-triazol-1-yl)ethoxy, 2-(N-(3-morpholinopropylsulphonyl)-N-methylamino)ethoxy, 2-(N-methyl-N-4-pyridyl)amino)ethoxy, 3-(4-oxidomorpholino)propoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 3-(2-(4-methylpiperazin-1-yl)ethoxy)propoxy, 2-(2-morpholinoethoxy)ethoxy, 3-(2-morpholinoethoxy)propoxy, 2-(tetrahydropyran-4-yloxy)ethoxy, 3-(tetrahydropyran-4-yloxy)propoxy, 2-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)vinyl, 3-((2-(pyrrolidin-1-yl)ethyl)carbamoyl)prop-2-en-1-yloxy, 1-(2-pyrrolidinylethyl)piperidin-4-ylmethoxy, 1-(3-pyrrolidinylpropyl)piperidin-4-ylmethoxy, 1-(2-piperidinylethyl)piperidin-4-ylmethoxy, 1-(3-piperidinylpropyl)piperidin-4-ylmethoxy, 1-(2-morpholinoethyl)piperidin-4-ylmethoxy, 1-(3-morpholinopropyl)piperidin-4-ylmethoxy, 1-(2-thiomorpholinoethyl)piperidin-4-ylmethoxy, 1-(3-thiomorpholinopropyl)piperidin-4-ylmethoxy, 1-(2-azetidinyethyl)piperidin-4-ylmethoxy, 1-(3-azetidinypropyl)piperidin-4-ylmethoxy, 3-morpholino-2-hydroxypropoxy, (2*R*)-3-morpholino-2-hydroxypropoxy, (2*S*)-3-morpholino-2-hydroxypropoxy, 3-piperidino-2-hydroxypropoxy, (2*R*)-3-piperidino-2-hydroxypropoxy, (2*S*)-3-piperidino-2-hydroxypropoxy, 3-pyrrolidin-1-yl-2-hydroxypropoxy, (2*R*)-3-pyrrolidin-1-yl-2-hydroxypropoxy, (2*S*)-3-pyrrolidin-1-yl-2-hydroxypropoxy, 3-(1-methylpiperazin-4-yl)-2-hydroxypropoxy, (2*R*)-3-(1-methylpiperazin-4-yl)-2-hydroxypropoxy, (2*S*)-3-(1-methylpiperazin-4-yl)-2-hydroxypropoxy, 3-(N,N-diethylamino)-2-hydroxypropoxy, (2*R*)-3-(N,N-diethylamino)-2-hydroxypropoxy, (2*S*)-3-(N,N-

A9 diethylamino)-2-hydroxypropoxy, 3-(isopropylamino)-2-hydroxypropoxy, (2R)-3-(isopropylamino)-2-hydroxypropoxy, (2S)-3-(isopropylamino)-2-hydroxypropoxy, 3-(N,N-diisopropylamino)-2-hydroxypropoxy, (2R)-3-(N,N-diisopropylamino)-2-hydroxypropoxy or (2S)-3-(N,N-diisopropylamino)-2-hydroxypropoxy.

* * * * *


Please replace subparagraph numbered 12) at page 38, line 13, with the following new subparagraph:

A10 12) C₁₋₅alkylX⁶R²⁹ (wherein X⁶ and R²⁹ are as defined hereinbefore);

* * * * *

Please replace the paragraph extending from page 47, line 26 to page 48, line 28 with the following amended paragraph:

In another aspect of the present invention there is provided the use of compounds of the formula Ia:



[wherein:

ring C, R¹, R², n and Z are as defined hereinbefore with the provisos that R² is not hydrogen and that Z is not CH₂ or a direct bond; and

R^{2a} represents hydrogen, halogeno, C₁₋₃alkyl, trifluoromethyl, C₁₋₃alkoxy, C₁₋₃alkylsulphanyl, -NR^{3a}R^{4a} (wherein R^{3a} and R^{4a}, which may be the same or different, each represents

Sub
B¹
Att

hydrogen or C₁₋₃alkyl), or R^{5a}(CH₂)_{za}X^{1a} (wherein R^{5a} is a 4- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), za is an integer from 0 to 4 and X^{1a} represents a direct bond, -O-, -CH₂-, -S-, -SO-, -SO₂-, -NR^{6a}C(O)-, -C(O)NR^{7a}-, -SO₂NR^{8a}-, -NR^{9a}SO₂- or -NR^{10a}- (wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} and R^{10a} each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl));
and salts thereof, and prodrugs thereof for example esters and amides, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans.

* * * * *

Please replace the first paragraph of Example 15 at page 111, extending from line 9 to line 13, with the following amended paragraph:

A12

Using a procedure analogous to that described for Example 9, 4-chloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (0.13g, 0.4mmol), (prepared as described for the starting material in Example 9), was reacted with 7-hydroxy-4-methylquinoline (80mg, 0.5mol), (Chem. Berich. 1967, 100, 2077), to give 6-methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (155mg, 87%).

* * * * *

Please replace the first paragraph of Example 16 at page 111, extending from line 20 to line 25, with the following amended paragraph:

A13
Using a procedure analogous to that described for Example 9, 4-chloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (0.13g, 0.4mmol), (prepared as described for the starting material in Example 9), was reacted with 2,2,4-trimethyl-1,2-dihydroquinolin-6-ol (95mg, 0.5mmol), (IZV. ACAD. NAVK. SSSR. Ser. Khim. 1981, 9, 2008), to give **6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline** (90mg, 47%).

* * * * *

Please replace the first paragraph of Example 18 at page 112, extending from line 12 to line 16, with the following amended paragraph:

A14
Using a procedure analogous to that described for Example 9, 4-chloro-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline (0.13g, 0.4mmol), (prepared as described for the starting material in Example 10), was reacted with 2,4-dimethyl-7-hydroxyquinoline (87mg, 0.5mmol), (Chem. Berichte, 1903, 36, 4016), to give **4-(2,4-dimethylquinolin-7-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline** (61mg, 33%).

* * * * *

Please replace the first paragraph of Example 19 at page 112, extending from line 23 to line 27, with the following amended paragraph:

A15
Using a procedure analogous to that described for Example 9, 4-chloro-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline (0.13g, 0.4mmol), (prepared as described for the starting material in Example 10), was reacted with 6-hydroxy-2H-4H-1,4-benzoxazin-3-one (83mg, 0.5mmol), (J. Chem. Soc. C, 1971, 2696), to give **6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(3-oxo-2H-4H-1,4-benzoxazin-6-yloxy)quinazoline** (158mg, 88%).

* * * * *

Replace the first paragraph of Example 20 at page 113, extending from line 2 to line 6, with the following new paragraph:

A16 Using a procedure analogous to that described for Example 9, 4-chloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (0.13g, 0.4mmol), (prepared as described for the starting material in Example 9), was reacted with 6-hydroxy-2H-4H-1,4-benzoxazin-3-one (83mg, 0.5mmol), (J. Chem. Soc. C, 1971, 2696), to give **6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(3-oxo-2H-4H-1,4-benzoxazin-6-yloxy)quinazoline** (170mg, 94%).

* * * * *

Please replace the first paragraph of Example 71 at page 140, extending from line 12 to line 23, with the following amended paragraph:

A17 Methoxyacetaldehyde (368mg, 3.47 mmol) (freshly distilled) followed by sodium triacetoxyborohydride (552mg, 2.6mol) were added to a solution of 6-methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline (726mg, 1.74mmol), (prepared as described in Example 70), in a mixture of methylene chloride (15ml) and methanol (15ml). After stirring for 1.5 hours at ambient temperature, saturated sodium hydrogen carbonate was added. The volatiles were removed under vacuum and the residue was partitioned between methylene chloride and water. The organic layer, was separated, washed with water, brine, dried (MgSO₄) and the volatiles were removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (80/20). After removal of the solvent, the residue was triturated with ether, collected by filtration, washed with ether and dried under vacuum at 60°C to give **6-methoxy-7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy)quinazoline** (392mg, 47%).

* * * * *

Please replace the first paragraph of Example 90 at page 153, extending from line 4 to line 12, with the following new paragraph:

A18 A solution of 7-hydroxy-4-(2-methylindol-5-yloxy)quinazoline (423 mg, 1.45 mmol), (prepared as described for the starting material in Example 82), triphenylphosphine (685 mg, 2.61 mmol), 4-hydroxymethyl-1-*tert*-butoxycarbonylpiperidine (500 mg, 2.32 mmol), (prepared as described for the starting material in Example 10), and diisopropyl azodicarboxylate (528 mg, 2.61 mmol) in methylene chloride (18 ml) was stirred overnight at ambient temperature. The mixture was then poured onto a column of silica and eluted with ethyl acetate. After evaporation of the solvent, the residue was triturated with ether, filtered, and dried under vacuum to give 7-(1-*tert*-butoxycarbonylpiperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy)quinazoline (478 mg, 68 %).

* * * * *

Please replace the paragraph of Example 126 at page 168 extending from line 19 to line 24, with the following amended paragraph:

A19 A solution of 2-(piperidin-4-yl)-1-ethanol (830 mg, 6.4 mmol) in DMF (5 ml) containing tertbutyl dicarbonate anhydride (1.4 g, 6.4 mmol) was stirred at ambient temperature for 48 hours. After removal of the volatiles under vacuum, the residue was partitioned between ether and water. The organic layer was separated, washed with water, brine, dried (MgSO₄) and evaporated to give 4-(2-hydroxyethyl)-(1-*tert*-butoxycarbonyl)piperidine (1 g, 68 %).

* * * * *

Please replace the first paragraph of Example 157 at page 189, extending from line 20 to line 28, with the following new paragraph: